RNS Number : 1302U MaxCyte, Inc. 21 January 2025 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 8160T MaxCyte, Inc. 17 January 2025 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 4815T MaxCyte, Inc. 15 January 2025 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
ROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a
RNS Number : 0527T MaxCyte, Inc. 13 January 2025 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, MD , January 13, 2025 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 9909R MaxCyte, Inc. 02 January 2025 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , January 2, 2025 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 6525R MaxCyte, Inc. 31 December 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 31, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that
RNS Number : 0232R MaxCyte, Inc. 23 December 2024 MaxCyte Announces Retirement of Board Member Art Mandell ROCKVILLE, MD , December 23, 2024 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 8225Q MaxCyte, Inc. 19 December 2024 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
